The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | BRUIN CLL-314 study: pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL/SLL
In this press briefing, Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares findings from the Phase III BRUIN CLL-314 study (NCT05254743) comparing pirtobrutinib versus ibrutinib in patients with treatment-naïve and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
